#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	3668	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2392	445.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1477	1477	C	497	C	456	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6060	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4118	440.6	0	.	n	.	0	T695C	SNP	695	695	T	1397	1397	C	452	C,A	405,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6060	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4118	440.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	2039	2039	A	557	A	505	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6060	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4118	440.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2673	2673	C	583	C	532	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6060	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4118	440.6	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3299	3299	T	524	T,C	473,3	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6060	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4118	440.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2747	2747	A	590	A	549	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	630	folP	852	852	100.0	folP.l15.c4.ctg.1	2181	86.3	1	SNP	p	R228S	1	.	.	682	684	AGC	1430	1432	AGC	131;130;129	A,G;G;C,G	118,1;117;115,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1176	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3910	90.0	1	SNP	p	S91F	0	.	.	271	273	TCC	810	812	TCC	92;92;92	T;C;C	87;89;88	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1176	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3910	90.0	1	SNP	p	D95G	0	.	.	283	285	GAC	822	824	GAC	96;95;95	G;A;C	93;90;91	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1176	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3910	90.0	1	SNP	p	D95N	0	.	.	283	285	GAC	822	824	GAC	96;95;95	G;A;C	93;90;91	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	486	mtrR	633	633	99.84	mtrR.l6.c4.ctg.1	1937	75.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	350	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1486	70.4	0	.	n	.	0	C187G	SNP	187	187	C	877	877	G	125	G	113	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1374	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3366	122.0	1	SNP	p	D86N	0	.	.	256	258	GAC	791	793	GAC	139;140;139	G;A,C;C	127;122,3;129	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1374	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3366	122.0	1	SNP	p	S87W	0	.	.	259	261	AGT	794	796	AGT	140;142;142	A;G;T	122;128;129	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1374	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3366	122.0	1	SNP	p	S87I	0	.	.	259	261	AGT	794	796	AGT	140;142;142	A;G;T	122;128;129	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1374	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3366	122.0	1	SNP	p	S87R	0	.	.	259	261	AGT	794	796	AGT	140;142;142	A;G;T	122;128;129	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1374	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3366	122.0	1	SNP	p	S88P	0	.	.	262	264	TCC	797	799	TCC	142;141;141	T;C;C	129;129;128	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1088	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3248	100.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1915	1917	GGC	136;136;135	G;G,T;C	124;122,1;122	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	942	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3030	93.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1540	1542	GCA	132;131;131	G;C;A	115;121;122	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	942	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3030	93.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1543	1545	ATC	129;129;130	A,C;T;C	119,1;117;120	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	942	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3030	93.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1555	1557	GTG	126;126;126	G;T;G	118;116;117	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	942	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3030	93.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1555	1557	GTG	126;126;126	G;T;G	118;116;117	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	942	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3030	93.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2059	2061	ACC	109;110;110	A,C;C;C	97,1;101;99	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	942	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3030	93.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2113	2115	GCG	109;109;107	G;C;G,C	93;87;84,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	942	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3030	93.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2113	2115	GCG	109;109;107	G;C;G,C	93;87;84,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	942	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3030	93.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2236	2238	GGC	127;127;126	G;G;C,G	108;115;111,2	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	942	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3030	93.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2245	2247	GGC	124;122;122	G;G;C,A	111;106;108,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	942	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3030	93.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2263	2265	CCG	126;128;126	C;C;G	106;116;108	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1382	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3639	113.9	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1870	1872	CTG	131;132;132	C;T;G,T	116;115;120,1	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	676	porA	1146	1146	99.83	porA.l15.c17.ctg.1	2440	83.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	862	862	C	102	C,A	89,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	106	porB1a	984	178	90.66	porB1a.l6.c30.ctg.1	938	21.6	0	.	p	.	0	H217N	NONSYN	649	651	CAT	490	492	AAT	11;11;11	A;A;T	11;11;11	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	106	porB1a	984	178	90.66	porB1a.l6.c30.ctg.1	938	21.6	0	.	p	.	0	D218N	NONSYN	652	654	GAT	493	495	AAT	11;11;11	A;A;T	11;11;11	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	106	porB1a	984	178	90.66	porB1a.l6.c30.ctg.1	938	21.6	0	.	p	.	0	A222V	NONSYN	664	666	GCT	505	507	GTT	11;11;11	G;T;T	11;11;11	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	106	porB1a	984	178	90.66	porB1a.l6.c30.ctg.1	938	21.6	0	.	p	.	0	V226A	NONSYN	676	678	GTA	517	519	GCA	10;10;10	G;C;A	10;10;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	106	porB1a	984	178	90.66	porB1a.l6.c30.ctg.1	938	21.6	0	.	p	.	0	.	MULTIPLE	700	702	ACT	540	542	GTA	9;9;9	G;T;A	9;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	106	porB1a	984	178	90.66	porB1a.l6.c30.ctg.1	938	21.6	0	.	p	.	0	N237fs	FSHIFT	709	709	A	549	549	A	9	A	9	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	828	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1833	132.7	0	.	p	.	0	G38E	NONSYN	112	114	GGA	555	557	GAA	165;164;162	G;A;A	144;145;147	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	828	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1833	132.7	0	.	p	.	0	S46G	NONSYN	136	138	AGC	579	581	GGC	162;163;164	G;G;C	141;143;142	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	828	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1833	132.7	0	.	p	.	0	E48G	NONSYN	142	144	GAA	585	587	GGA	163;163;160	G,T;G;A	144,1;144;147	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	828	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1833	132.7	0	.	p	.	0	T87A	NONSYN	259	261	ACT	702	704	GCT	165;165;164	G,T;C;T,G	147,1;145;142,2	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	828	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1833	132.7	0	.	p	.	0	T89S	NONSYN	265	267	ACC	708	710	AGC	166;167;166	A;G;C	150;153;151	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	828	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1833	132.7	0	.	p	.	0	.	MULTIPLE	358	359	AA	800	801	CG	173;173	C,A;G	159,1;160	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	828	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1833	132.7	0	.	p	.	0	.	MULTIPLE	361	362	GA	803	805	CAG	172;172;173	C;A;G	154;159;157	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	828	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1833	132.7	0	.	p	.	0	N122K	NONSYN	364	366	AAC	807	809	AAA	173;172;171	A,C;A,G;A,C	155,1;152,1;150,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	828	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1833	132.7	0	.	p	.	0	K143E	NONSYN	427	429	AAA	870	872	GAA	170;171;172	G,C;A,C;A	160,1;159,1;164	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	828	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1833	132.7	0	.	p	.	0	V151A	NONSYN	451	453	GTA	894	896	GCA	167;166;166	G;C,T;A	156;154,1;156	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	828	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1833	132.7	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	1002	1004	CGA	152;153;155	C,A;G;A	135,1;139;142	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	828	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1833	132.7	0	.	p	.	0	A215T	NONSYN	643	645	GCT	1086	1088	ACT	152;152;151	A;C,T;T,C	136;135,1;132,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	828	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1833	132.7	0	.	p	.	0	Y216H	NONSYN	646	648	TAT	1089	1091	CAT	149;150;149	C;A;T	137;136;137	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	828	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1833	132.7	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1095	1097	ATG	147;147;147	A;T;G,A	137;134;132,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	828	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1833	132.7	0	.	p	.	0	.	MULTIPLE	766	767	AC	1209	1211	GCA	158;158;156	G;C;A	149;146;144	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	828	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1833	132.7	0	.	p	.	0	W257R	NONSYN	769	771	TGG	1213	1215	CGG	154;154;153	C;G;G	146;148;140	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	828	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1833	132.7	0	.	p	.	0	S258fs	FSHIFT	772	772	A	1216	1216	A	153	A,G	137,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	828	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1833	132.7	1	SNP	p	G120K	1	.	.	358	360	AAG	800	802	CGG	173;173;170	C,A;G;G,T	159,1;160;152,1	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	828	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1833	132.7	1	SNP	p	A121D	1	.	.	361	363	GAC	803	806	CGC	172;173;172	C;G;C	154;157;154	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	828	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1833	132.7	1	SNP	p	D121N	0	.	.	361	363	GAC	803	806	CGC	172;173;172	C;G;C	154;157;154	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2454	rpoB	4179	4179	100.0	rpoB.l6.c17.ctg.1	5784	127.3	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2585	2587	AAT	149;149;149	A;A;T	134;136;131	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	416	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1683	74.0	1	SNP	p	V57M	1	.	.	169	171	ATG	895	897	ATG	133;133;132	A;T;G	123;124;125	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
